Spero granted up to $12.9M by BARDA to develop urinary tract infection drug for children

Jan. 19, 2022 3:22 PM ETSpero Therapeutics, Inc. (SPRO)By: Ravikash, SA News Editor
  • Spero Therapeutics (SPRO -2.2%) said the Biomedical Advanced Research and Development Authority (BARDA) awarded up to an additional $12.9M to the company to to develop tebipenem as a treatment for complicated urinary tract infections (cUTI), including pyelonephritis, in pediatric patients.
  • BARDA, a division under the U.S. Department of Health and Human Services, added, and exercised, a new option on the contract originally awarded to Spero in 2018.
  • The new option increases the total amount of committed funding by $12.9M to $46.9M, increasing the total potential contract value to $59.7M.
  • The company previously noted that the Defense Threat Reduction Agency is providing up to ~$10M, in addition to the total potential award from BARDA, to cover the cost of the nonclinical biodefense aspects of the collaboration program for tebipenem HBr.
  • The additional $12.9M option is expected to provide support for a clinical trial and related activities for orally administered tebipenem pivoxil’s use in treating children with cUTI, including AP.
  • Earlier in January, Spero received U.S. FDA priority review for oral tebipenem HBr to treat urinary tract infections.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.